This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Radiopharmaceuticals & Imaging
March 14, 2023
Digital Conference8:00AM EDT // 12:00PM GMT // 1:00PM CET

Michael Schultz
Chief Science Officer at Perspective Therapeutics, USA


Michael K Schultz PhD is a funded NIH investigator, Founder and Chief Science Officer of Viewpoint Molecular Targeting, Inc., and a tenured Associate Professor of Radiology, Pediatrics, Free Radical and Radiation Biology, and Chemistry at the University of Iowa. Dr. Schultz has been involved in peptide-based radiopharmaceutical research and the development of new imaging and therapy agents for cancer for nearly 20 years and has been a Project Leader in the NETs Specialized Program of Research Excellence (SPORE) team at the University of Iowa since 2015. His expertise is cancer radiopharmaceutical sciences, radiochemistry, radiation biology, cancer oxidative metabolism and drug resistance, and bioconjugate chemistry with a focus on receptor targeted imaging-guided alpha-particle therapy for cancer. His recent publications demonstrate the potential for alpha-particle targeted radionuclide therapy; dosimetry of 212Pb based peptides; production of 203Pb/212Pb radiopharmaceuticals; ligand design; and generator produced radionuclides. Dr. Schultz and Viewpoint Co-founder Frances Johnson MD have secured approximately $18M in peer-reviewed grants and contracts from the National Cancer Institute of the National Institutes of Health. The team continues to secure the private capital investment needed to advance 203Pb/212Pb image-guided radionuclide therapy for cancer to global availability. The company has been granted safe to proceed designations for two imaging trials and two therapeutic trials for its peptide-based 203Pb imaged-guided 212Pb alpha particle therapy for metastatic melanoma and neuroendocrine tumors and has recently received Fastrack designation by the US FDA for its alpha particle therapy for neuroendocrine tumors.

Agenda Sessions

  • Peptide Based Pb-203/Pb-212 Image-Guided Alpha-Particle Receptor-Targeted Radionuclide Therapy for Cancer: Matching up Physics, Biology, and Isotope Supply